UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

Oncogene, 2007-10, Vol.26 (49), p.6997-7005

2007

Volltextzugriff (PDF)

AIB1 is a predictive factor for tamoxifen response in premenopausal women

Annals of oncology, 2010-02, Vol.21 (2), p.238-244

2010

Volltextzugriff (PDF)

Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

The Journal of pathology, 2009-02, Vol.217 (3), p.372-379

2009

Volltextzugriff (PDF)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Annals of oncology, 2013-08, Vol.24 (8), p.1994-1999

2013

Volltextzugriff (PDF)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.313-322

2016

Volltextzugriff (PDF)

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Journal of clinical oncology, 2022-12, Vol.40 (35), p.4071-4082

2022

Volltextzugriff (PDF)

300P Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up

Annals of oncology, 2024-09, Vol.35, p.S340-S340

2024

Volltextzugriff (PDF)

409P Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up

Annals of oncology, 2024-09, Vol.35, p.S390-S390

2024

Volltextzugriff (PDF)

316P Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials

Annals of oncology, 2024-09, Vol.35, p.S346-S346

2024

Volltextzugriff (PDF)

Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma

The Lancet (British edition), 1992-12, Vol.340 (8832), p.1369-1373

1992

Volltextzugriff (PDF)

315P Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer

Annals of oncology, 2024-09, Vol.35, p.S346-S346

2024

Volltextzugriff (PDF)

Proteomics-based characterization of potential biomarkers in tamoxifen resistance in breast cancer

JOURNAL OF CLINICAL ONCOLOGY, 2011, Vol.29 (15_suppl), p.628-628

2011

Volltextzugriff (PDF)

LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

Annals of oncology, 2021-05, Vol.32, p.S21

2021

Volltextzugriff (PDF)

6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

Annals of oncology, 2021-05, Vol.32, p.S23

2021

Volltextzugriff (PDF)

IP6K2 predicts favorable clinical outcome of primary breast cancer

Molecular and clinical oncology, 2021-05, Vol.14 (5), p.94-94, Article 94

2021

Volltextzugriff (PDF)

Increased long-term risk of fatal breast cancer in patients with high intra-tumor heterogeneity of the estrogen receptor – Retrospective analyses of the STO-3 trial

ANNALS OF ONCOLOGY, 2017, Vol.28, p.i10

2017

Volltextzugriff (PDF)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Molecular and clinical oncology, 2020, Vol.12 (5), p.415-420

2020

Volltextzugriff (PDF)

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

Journal of clinical pathology, 2005-11, Vol.58 (11), p.1135-1142

2005

Volltextzugriff (PDF)

125P Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

Breast cancer research and treatment, 2005-05, Vol.91 (2), p.145-151

2005

Volltextzugriff (PDF)

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

Annals of oncology, 2000-12, Vol.11 (12), p.1545-1550

2000

Volltextzugriff (PDF)

Amplification of HSD17B1 and ERBB2 in primary breast cancer

Oncogene, 2003-01, Vol.22 (1), p.34-40

2003

Volltextzugriff (PDF)

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Acta oncologica, 2024-07, Vol.63 (1), p.535-541

2024

Volltextzugriff (PDF)

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

JNCI : Journal of the National Cancer Institute, 2018-07, Vol.110 (7), p.726-733

2018

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Full Text

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(122)

Publikationsform

Artikel
(117)
Tagungsberichte
(12)

Sprache

Englisch
(129)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

AIB1 is a predictive factor for tamoxifen response in premenopausal women

Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

300P Gene expression landscape of the long-term tamoxifen resistance in premenopausal ER+ breast cancer patients in the STO-5 controlled randomized clinical trial with >20-year follow-up

409P Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up

316P Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials

Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma

315P Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer

Proteomics-based characterization of potential biomarkers in tamoxifen resistance in breast cancer

LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

IP6K2 predicts favorable clinical outcome of primary breast cancer

Increased long-term risk of fatal breast cancer in patients with high intra-tumor heterogeneity of the estrogen receptor – Retrospective analyses of the STO-3 trial

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

125P Components of the PI3K/Akt pathway as prognostic factors in metastatic HER2-positive breast cancer treated with trastuzumab

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

Amplification of HSD17B1 and ERBB2 in primary breast cancer

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer

Aktive Filter

Suchergebnisse filtern